Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352779 · ClinicalTrials.gov registry record · NA
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
A NA study, sponsored by Gary Morrow.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT02352779 is a NA study that has completed, run by Gary Morrow. The registered enrollment target is 108 participants.
The verdict
NCT02352779, a NA study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies omega-3 fatty acid in reducing cancer-related fatigue in breast cancer survivors. Supplementation with omega-3 fatty acid may help reduce cancer-related fatigue in breast cancer survivors.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DIETARY_SUPPLEMENT Omega-3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352779
The ClinicalTrials.gov registry entry for NCT02352779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02352779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352779 about?
NCT02352779 is a clinical study titled "Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors". This randomized pilot clinical trial studies omega-3 fatty acid in reducing cancer-related fatigue in breast cancer survivors. Supplementation with omega-3 fatty acid may help reduce cancer-related fatigue in breast cancer survivors.
What is the current status of trial NCT02352779?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2015-02. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02352779?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Omega-3 Fatty Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02352779?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.